Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MB-002 in metastatic renal cell carcinoma
NCT00087984Phase 2Completed
- Sponsor
- Argos Therapeutics
- Start
- Jan 2004
- Primary completion
- Sep 2008
- Modality
- Whole Cell Cancer Vaccines, Dendritic Cell Vaccines
- Countries
- 2
01
Overview
A Phase 2 trial of MB-002 in renal cell carcinoma (RCC), sponsored by Argos Therapeutics. Started Jan 2004; status: completed.
02
Drugs
MB-002
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT00087984.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00087984.